Ticker: BSPM, Company: Biostar Pharmaceuticals, Inc., Type: 10-K, Date: 2013-04-15, XBRL Interactive Financials
Original SEC Filing: Click here

---

Webplus: BSPM/20130415/10-K/1/000.htm SEC Original: biostar10k123112.htm
FORM 10-K (Mark One) x December 31, 2012 For the fiscal year ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China

---

---

Webplus: BSPM/20130415/10-K/2_EX-10.7/000.htm SEC Original: ex10-7.htm
Product Research and Developmentreement Party A: Shaanxi Aoxing Pharmaceutical Party B: Lifeience Academy of Northwest University Party A and Party B reached the following R&Dreement regarding National Type I new medicinenshensu Borneol Ester through friendly negotiation: 2. Project research progress: (1) Party B has finished the research of DBZs activity, technical, quality standard and stability.

---

---

Webplus: BSPM/20130415/10-K/3_EX-23.1/000.htm SEC Original: ex23-1.htm
Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, We herebynsent to theorporation by reference in the Registration Statement on Forms S-8 (No. 333-161598) and S-8 (No. 333-183387) of Biostar Pharmaceuticals, of our reportted April 11, 2013 relating to thensolidated financial statements, which appears in the Annual Report on

---

---

Webplus: BSPM/20130415/10-K/4_EX-23.2/000.htm SEC Original: ex23-2.htm
CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM To the Board of Directors of Biostar Pharmaceuticals, Mazars CPA Limited Mazars CPA Limited Certified Public Accountants Hong Kong April 11, 2013 ex23-2.htm 4 EX-23.2

---

---

Webplus: BSPM/20130415/10-K/5_EX-31.1/000.htm SEC Original: ex31-1.htm
CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with

---

---

Webplus: BSPM/20130415/10-K/6_EX-31.2/000.htm SEC Original: ex31-2.htm
CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with

---

---

Webplus: BSPM/20130415/10-K/7_EX-32.1/000.htm SEC Original: ex32-1.htm
CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated.ted: April 15, 2013 Ronghua Wang Chief Executive Officer ex32-1.htm 7 EX-32.1

---

---

Webplus: BSPM/20130415/10-K/8_EX-32.2/000.htm SEC Original: ex32-2.htm
CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated.ted: April 15, 2013 Qinghua Liu Interim Chief Financial Officer (principal financial officer) ex32-2.htm 8 EX-32.2

---

Company Information:

Ticker: BSPM, Company: Biostar Pharmaceuticals, Inc., Type: 10-K, Date: 2013-04-15, XBRL Interactive FinancialsCIK: 0001418133, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
NO. 588 SHIJI XI AVENUE
XIANYANG, SHAANXI PROVINCE 712046